0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > ROR1

ROR1

Brief Information

Name:Inactive tyrosine-protein kinase transmembrane receptor ROR1
Target Synonym:EC 2.7.10.1,Inactive tyrosine-protein kinase transmembrane receptor ROR1,NTRKR1,ROR1,Receptor Tyrosine Kinase Like Orphan Receptor 1,Neurotrophic Tyrosine Kinase, Receptor-Related 1,DJ537F10.1,ROR-1
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Phase 3 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
ROR1 mAb - 01 Lead Hematological Malignancy,AutoImmunity Solid tumor,Blood tumor

Product ListCompare or Buy

Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
RO1-M82E3 Mouse Biotinylated Mouse ROR1 Protein, His,Avitag™ (MALS verified)
RO1-M82E3-structure
RO1-M82E3-sds
RO1-M82F3 Mouse Biotinylated Mouse ROR1 Protein, Fc,Avitag™ (MALS verified)
RO1-M82F3-structure
RO1-M82F3-sds
RO1-HP2H5 Human PE-Labeled Human ROR1 Protein, His TagStar Staining
RO1-HP2H5-structure
RO1-HA2H4 Human APC-Labeled Human ROR1 Protein, His TagStar Staining
RO1-HA2H4-structure
CEA-B050 Human ClinMax™ Human Soluble ROR1 ELISA Kit,PRO
RO1-HA2H7 Human Alexa Fluor™ 488-Labeled Human ROR1 Protein, His TagStar Staining
RO1-HA2H7-structure
SCCHO-ATP083 Human CHO/Human ROR1 Stable Cell Line Development Service
CHEK-ATP084 Human HEK293/Human ROR1 Stable Cell Line
RO1-HP2E3 Human PE-Labeled Human ROR1 Protein, His Tag (Site-specific conjugation)
RO1-HP2E3-structure
RO1-HF253 Human FITC-Labeled Human ROR1 Protein, Fc Tag
RO1-HF253-structure
RO1-HF253-sds
RO1-HF258 Human FITC-Labeled Human ROR1 Protein, His Tag
RO1-HF258-structure
RO1-HF258-sds
RO1-H5256 Human / Cynomolgus / Rhesus macaque Human / Cynomolgus / Rhesus macaque ROR1 Protein, Mouse IgG2a Fc Tag (MALS verified)
RO1-H5256-structure
RO1-H5256-sds
MBR-K009 Human Human ROR1-coupled Magnetic Beads
RO1-H82E6 Human / Cynomolgus / Rhesus macaque Biotinylated Human / Cynomolgus / Rhesus macaque ROR1 Protein, His,Avitag™ (MALS verified)
RO1-H82E6-structure
RO1-H82E6-sds
RO1-H821y Human / Cynomolgus / Rhesus macaque Biotinylated Human / Cynomolgus / Rhesus macaque ROR1 Protein, Avitag™ (MALS verified)
RO1-H821y-structure
RO1-H821y-sds
RO1-R5221 Rat Rat ROR1 Protein, His Tag (MALS verified)
RO1-R5221-structure
RO1-R5221-sds
RO1-H82F4 Human / Cynomolgus / Rhesus macaque Biotinylated Human / Cynomolgus / Rhesus macaque ROR1 Protein, Fc,Avitag™ (MALS verified)
RO1-H82F4-structure
RO1-H82F4-sds
RO1-H5223 Human Human / Cynomolgus / Rhesus macaque ROR1 (308-395, Kringle domain) Protein, His Tag (MALS verified)
RO1-H5223-structure
RO1-H5223-sds
RO1-H5222 Human / Cynomolgus / Rhesus macaque Human / Cynomolgus / Rhesus macaque ROR1 (165-305, Frizzled domain) Protein, His Tag (MALS verified)
RO1-H5222-structure
RO1-H5222-sds
RO1-H5221 Human / Cynomolgus / Rhesus macaque Human / Cynomolgus / Rhesus macaque ROR1 (39-151, Ig-like domain) Protein, His Tag (MALS verified)
RO1-H5221-structure
RO1-H5221-sds
RO1-M5250 Mouse Mouse ROR1 Protein, Fc Tag (MALS verified)
RO1-M5250-structure
RO1-M5250-sds
RO1-M5221 Mouse Mouse ROR1 Protein, His Tag (MALS verified)
RO1-M5221-structure
RO1-M5221-sds
RO1-H522y Human / Cynomolgus / Rhesus macaque Human / Cynomolgus / Rhesus macaque ROR1 Protein, His Tag (MALS verified)
RO1-H522y-structure
RO1-H522y-sds
RO1-H5250 Human / Cynomolgus / Rhesus macaque Human / Cynomolgus / Rhesus macaque ROR1 Protein, Fc Tag (MALS verified)
RO1-H5250-structure
RO1-H5250-sds
ACRO Quality

Part of Bioactivity data

CHEK-ATP084-Cell-based assay
 ROR1 FACS

Expression analysis of human ROR1 on HEK293/Human ROR1 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human ROR1 Stable Cell Line or negative control cell using PE-labeled anti-human ROR1 antibody.

RO1-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-ROR1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human ROR1 Protein, His Tag (Cat. No. RO1-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

RO1-H82E6-SPR
 ROR1 SPR

Anti-Human ROR1 mAb captured on CM5 chip via anti-mouse antibodies surface can bind Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, His, Avitag (Cat. No. RO1-H82E6) with an affinity constant of 5.81 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

RO1-H82E6-SPR
 ROR1 SPR

Zilovertamab captured on Protein A Chip can bind Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, His,Avitag (Cat. No. RO1-H82E6) with an affinity constant of 112 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

ROR1,NTRKR1

Background

The biotinylated ROR1 protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-ROR1 antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This ROR1 coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Zilovertamab vedotin VLS-101; MK-2140 Phase 3 Clinical Oncternal Therapeutics Inc, University Of California San Diego Breast Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Richter's Syndrome; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Stomach Neoplasms; Lymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Hematologic Neoplasms Details
Zilovertamab UC-961 Phase 2 Clinical University Of California San Diego, Oncternal Therapeutics Inc Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Immunoproliferative Disorders; Lymphatic Diseases; Immune System Diseases; Prostatic Neoplasms, Castration-Resistant; Lymphoma, Mantle-Cell; Breast Neoplasms; Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
ONCT-808 ONCT-808 Phase 2 Clinical Oncternal Therapeutics Inc Lymphoma, B-Cell; Neoplasms Details
Nebratamig GNC-035 Phase 2 Clinical Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
EMB-07 EMB-07 Phase 1 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Uterine Neoplasms; Neoplasm Metastasis Details
PB-004 PB004; PBA-0405; PB004 PureBIKE; PB-004 Phase 1 Clinical Pure Biologics SA Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Sarcoma Details
PRGN-3007 PRGN-3007 Phase 1 Clinical Precigen Inc Hematologic Neoplasms; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
LYL-797 LYL-797 Phase 1 Clinical Lyell Immunopharma Inc Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
NVG-111 NVG-111 Phase 1 Clinical NovalGen Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Melanoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell Details
LCB-71 CS-5001; LCB-71; ABL-202 Phase 1 Clinical Legochem Biosciences Inc, Abl Bio Inc Solid tumours; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma Details
SIM-201 SIM-201; SIM-0201 Phase 1 Clinical Jiangsu Simcere Pharmaceutical Co Ltd Solid tumours Details
Zilovertamab vedotin VLS-101; MK-2140 Phase 3 Clinical Oncternal Therapeutics Inc, University Of California San Diego Breast Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; Lymphoma, T-Cell; Leukemia, Myeloid, Acute; Richter's Syndrome; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Stomach Neoplasms; Lymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Hematologic Neoplasms Details
Zilovertamab UC-961 Phase 2 Clinical University Of California San Diego, Oncternal Therapeutics Inc Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Immunoproliferative Disorders; Lymphatic Diseases; Immune System Diseases; Prostatic Neoplasms, Castration-Resistant; Lymphoma, Mantle-Cell; Breast Neoplasms; Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
ONCT-808 ONCT-808 Phase 2 Clinical Oncternal Therapeutics Inc Lymphoma, B-Cell; Neoplasms Details
Nebratamig GNC-035 Phase 2 Clinical Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
EMB-07 EMB-07 Phase 1 Clinical Shanghai Epimab Biotherapeutics, Inc Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Lymphoma; Uterine Neoplasms; Neoplasm Metastasis Details
PB-004 PB004; PBA-0405; PB004 PureBIKE; PB-004 Phase 1 Clinical Pure Biologics SA Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Sarcoma Details
PRGN-3007 PRGN-3007 Phase 1 Clinical Precigen Inc Hematologic Neoplasms; Solid tumours; Lymphoma, Large B-Cell, Diffuse; Triple Negative Breast Neoplasms; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details
LYL-797 LYL-797 Phase 1 Clinical Lyell Immunopharma Inc Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
NVG-111 NVG-111 Phase 1 Clinical NovalGen Ltd Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Melanoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell Details
LCB-71 CS-5001; LCB-71; ABL-202 Phase 1 Clinical Legochem Biosciences Inc, Abl Bio Inc Solid tumours; Lymphoma, B-Cell; Hematologic Neoplasms; Lymphoma Details
SIM-201 SIM-201; SIM-0201 Phase 1 Clinical Jiangsu Simcere Pharmaceutical Co Ltd Solid tumours Details

This web search service is supported by Google Inc.

totop

Nachricht schicken